Emerging roles of and therapeutic strategies targeting BRD4 in cancer
- 1 March 2019
- journal article
- review article
- Published by Elsevier in Cellular Immunology
- Vol. 337, 48-53
Abstract
No abstract availableKeywords
Funding Information
- NIH (T32 CA090223)
This publication has 51 references indexed in Scilit:
- TAMeless traitors: macrophages in cancer progression and metastasisBritish Journal of Cancer, 2017
- Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammationCurrent Opinion in Chemical Biology, 2017
- Transcriptional Addiction in CancerCell, 2017
- BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid LeukemiaMolecular Cell, 2015
- Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growthOncogene, 2014
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaBlood, 2012
- Bromodomains as therapeutic targetsExpert Reviews in Molecular Medicine, 2011
- Epigenetic Mechanisms in InflammationJournal of Dental Research, 2010
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology: Seminars and Original Investigations, 2010
- Brd4-Independent Transcriptional Repression Function of the Papillomavirus E2 ProteinsJournal of Virology, 2007